Imara gets a second shot in sickle cell
Will upping the dose and changing the primary endpoint pay off?
Go or no go? Pdufa resolutions eyed for J&J and Amryt
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Ash 2021 – Forma takes on a second Agios drug
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
Ash 2021 – Global Blood stems the bleeding
The company reports decent data with its Oxbryta follow-on, but still has much to prove.
Ash 2021 – Agios and Forma take different paths in sickle cell disease
Forma still hopes for accelerated approval of etavopivat, while Agios believes that taking its time with mitapivat will pay off.
